Baierbrunn (ots) - Weltweit nehmen Resistenzen gegen Antibiotika zu. Damit bakterielle Infektionen auch ...
ots Ad hoc-Service: Antwerpes AG
In the first quarter of 2000, antwerpes ag almost doubles its results compared with the same quarter a year ago, achieving an EBITDA of 17%.
The sender is solely responsible for the contents of this announcement. -----------------------------------------------------
Cologne (ots Ad hoc-Service) -In the first quarter of 2000, antwerpes ag almost doubles its results compared with the same quarter a year ago, achieving an EBITDA of 17%.
* Turnover up by 70%, overall performance by 94%. * An EBITDA of 17% and an EBIT of 6%. * All divisions achieved planned turnovers, while profits exceeded plan. * DocCheck acquired several large orders in the field of clinical research in the first quarter.
antwerpes ag, Cologne, listed on the New Market since 17/4/00, increased its overall performance in the first quarter of 2000 compared with the same quarter in 1999 by 94% to DM 3,092,000 purely through internal growth (the overall performance represents the best description of the company's operations since it includes projects already being worked on but which have not yet been settled). Turnover increased by 70%. A margin of 17% was achieved before depreciations. The EBIT margin came to 6%. As a result, alt business units are on track to meet planned turnovers for fiscal 2000. Profits could well exceed plan for the total year. Despite the abnormal growth, the investments in the healthcare gateway DocCheck and the internal expenditures for the market placement, antwerpes ag was nevertheless able to continue to be profitable. The strong dynamic growth of antwerpes ag extended to all business units. New Media was able to increase its turnover by 94% and gain many profitable contracts for new and existing customers, including Otelo, Bewag, Berlin Chemie, Procter & Gamble Pharmaceuticals and the German Parkinson's Association. Our Classic Media division grew by 27.6%, acquiring the entire contract for the "Lovelle" contraceptive from Organon and receiving another large-scale order from Stadapharm GmbH. The most dynamic growth in the antwerpes Group was achieved by the healthcare gateway DocCheck. With its first quarter of DM 269,000, DocCheck generated almost the same turnover as in the whole of fiscal 1999. Furthermore DocCheck was able to acquire several large orders in the field of clinical research. The division also increased its users and websites considerably. By the end of the quarter DocCheck already had over 36,000 users and was responsible for the access management of more than 175 pharmaceutical websites. This represents an increase in users of 223% and 196% for websites compared with the first quarter of 1999. At the close of the first quarter. 9 out of 10 of the leading pharmaceutical manufacturers in Germany were using DocCheck access security for one or more of their websites. The company was therefore able, in the first quarter, to increase its market leadership as the largest and fastest growing Internet gateway for medical professionals in Europe. You will find the complete quarterly report on the Internet at www.antwerpes.de.
Your contact at antwerpes ag is:
Tanja Mumme Vogelsanger Straße 66 50823 Cologne Telephone: 0221/92053-139 Fax: 0221/92053-133 e-mail: ir(S)antwerpes.de Home page: www.antwerpes.de
antwerpes ag develops and implements Internet strategies and products in the healthcare and business-to-business (B2B) market. Operations are divided into the business units "Communication", "Tools" and "Consulting". Its subsidiary in the Communication area, antwerpes & partner ag, has grown into one of the leading new media service providers in Germany. The company is the market leader in the healthcare sector. In the Tools division, operating under the trade name DocCheck, antwerpes ag owns the largest and fastest growing Internet gateway for medical professionals in the European healthcare market. DocCheck brings the pharmaceutical industry and doctors together on the internet. The DocCheck products represent the benchmarks for B2B transaction models and pharmaceutical marketing in the future in the fields of e-commerce (MediMail), market research (MediMafo), clinical research (studie.de) and direct marketing (MediMail).
End of message ----------------------------------------------------- Internet: http://recherche.newsaktuell.deOriginal-Content von: antwerpes AG, übermittelt durch news aktuell